ArticleCureus2024
Genomics and Drug Discovery Strategies: The Role of Natural Compounds and Its Receptor in Alzheimer's Disease.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's Disease (AD) is a special class of neurodegenerative diseases demarcated as a progressive disorder affecting especially older adults globally. The AD-infected brain shows declination in cognitive functions, memory loss, and other exhausting symptoms. In this study, we focused on using advanced bioinformatics and next-generation sequencing to explore essential clusters of genes from various diversified Alzheimer's, Parkinson and Frontotemporal Dementia diseased cases. The significant differential expression analysis of genes (p-value ≤ 0.05, log fold change ≤ 0.05) was carried out, followed by meta-analysis, which resulted in the identification of 20 conserved genes across variable case studies. Out of 20 conserved genes, CASP8 and PTPN11 were observed to show essential regulatory mechanisms in AD metabolic pathways and proceeded further for docking analysis. Moreover, the natural compounds were screened for ligand library preparation based on extensive scientific literature and (ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity)) property check. Molecular docking was carried out with screened ligands and target receptors, resulting in the identification of Rosmarinic acid (RA) with CASP8 having docked score (∆G = -8.0 kcal/mol); Donepezil (FDA drug) dock score (∆G = -7.3 kcal/mol) (control). PTPN11 receptor with Carnosol ligand resulted in docking score (∆G = -9.1 kcal/mol) w.r.t Tacrine (FDA drug) docked score (∆G = -8.0 kcal/mol) followed by MD simulation. This research will aid in the identification of potential natural compounds that future researchers can use for further validation as a potential candidate drug in combating various neurodegenerative diseases highlighting AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.